tiprankstipranks
Trending News
More News >
Bachem Holding AG Class B (CH:BANB)
:BANB

Bachem Holding AG (BANB) AI Stock Analysis

Compare
1 Followers

Top Page

CH

Bachem Holding AG

(LSE:BANB)

Rating:76Outperform
Price Target:
CHF60.00
▲(10.60%Upside)
Bachem Holding AG scores well due to its strong financial performance, supported by solid revenue growth and stable profitability metrics. The technical indicators suggest positive momentum, though the high P/E ratio indicates potential overvaluation. The absence of recent earnings call details or notable corporate events limits further insights into immediate operational strategies.

Bachem Holding AG (BANB) vs. iShares MSCI Switzerland ETF (EWL)

Bachem Holding AG Business Overview & Revenue Model

Company DescriptionBachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.
How the Company Makes MoneyBachem Holding AG generates revenue primarily through the production and sale of peptides and oligonucleotides, which are essential components in pharmaceutical research and development. The company's key revenue streams include custom synthesis services, where they manufacture these molecules according to client specifications, and catalog products, which are standard offerings for research and development purposes. Bachem collaborates with pharmaceutical companies, biotech firms, and academic institutions, leveraging its advanced production capabilities to support drug development pipelines. Additionally, strategic partnerships and long-term supply agreements with major pharmaceutical companies contribute significantly to its revenue, ensuring a stable and recurring income stream.

Bachem Holding AG Financial Statement Overview

Summary
Bachem Holding AG demonstrates strong financial performance with consistent revenue growth, stable gross profit margins, and healthy net profit margins. The balance sheet reflects low leverage and a robust capital structure, while cash flow management is strong despite recent high capital expenditures impacting free cash flow.
Income Statement
85
Very Positive
Bachem Holding AG has shown a strong revenue growth rate with revenues increasing consistently year over year. The gross profit margin is stable, indicating good control over production costs. Net profit margins are healthy, supported by increasing net income over the past few years. EBIT and EBITDA margins are strong, showcasing efficient operations. The company has demonstrated solid growth and profitability in the medical pharmaceuticals sector.
Balance Sheet
80
Positive
The company maintains a low debt-to-equity ratio, reflecting low leverage and financial stability. The return on equity is robust, indicating effective use of equity to generate profits. The equity ratio is high, underscoring a strong capital structure. Bachem has increased its total assets significantly, primarily funded by equity, which reduces potential risks associated with high leverage.
Cash Flow
75
Positive
Bachem Holding AG exhibits strong operating cash flow relative to net income, indicating effective cash generation from operations. However, the free cash flow has been negative recently due to high capital expenditures, which could limit liquidity in the short term. Despite this, the company's investment in growth seems to be strategically driven.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
605.26M577.32M531.74M503.23M402.00M
Gross Profit
182.56M176.96M171.28M166.73M128.91M
EBIT
133.05M129.38M126.31M128.04M95.80M
EBITDA
178.76M163.28M157.08M156.47M121.72M
Net Income Common Stockholders
120.25M111.86M100.68M114.68M78.06M
Balance SheetCash, Cash Equivalents and Short-Term Investments
95.20M298.53M268.43M442.36M23.50M
Total Assets
1.92B1.68B1.38B1.30B710.88M
Total Debt
290.00K401.00K691.00K20.86M107.55M
Net Debt
-94.91M-157.32M-30.76M-68.33M84.06M
Total Liabilities
531.88M362.36M214.21M177.50M235.17M
Stockholders Equity
1.39B1.32B1.17B1.12B475.71M
Cash FlowFree Cash Flow
-138.30M-18.54M-49.76M-19.66M45.53M
Operating Cash Flow
146.32M249.86M92.59M97.16M114.63M
Investing Cash Flow
-148.88M-170.81M-63.17M-469.13M-69.31M
Financing Cash Flow
-61.26M48.69M-86.93M437.58M-42.66M

Bachem Holding AG Technical Analysis

Technical Analysis Sentiment
Positive
Last Price54.25
Price Trends
50DMA
49.96
Positive
100DMA
52.77
Positive
200DMA
59.89
Negative
Market Momentum
MACD
1.10
Negative
RSI
60.13
Neutral
STOCH
78.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:BANB, the sentiment is Positive. The current price of 54.25 is above the 20-day moving average (MA) of 52.06, above the 50-day MA of 49.96, and below the 200-day MA of 59.89, indicating a neutral trend. The MACD of 1.10 indicates Negative momentum. The RSI at 60.13 is Neutral, neither overbought nor oversold. The STOCH value of 78.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:BANB.

Bachem Holding AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
CHF4.15B34.488.87%1.55%4.84%7.45%
54
Neutral
$5.41B3.27-45.10%3.29%16.81%0.02%
CHF1.01B7.5829.55%3.19%
$5.39B26.0618.36%0.42%
$2.71B34.254.84%1.74%
61
Neutral
CHF701.91M
3.15%62.88%
CHF4.24B23.33
2.69%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CH:BANB
Bachem Holding AG
54.25
-22.61
-29.41%
GB:0RGI
COSMO Pharmaceuticals N.V.
58.80
-7.36
-11.12%
SGFEF
Siegfried Holding AG
109.92
13.83
14.39%
TCHBF
Tecan Group AG
206.10
-133.74
-39.35%
CH:PPGN
PolyPeptide Group AG
20.40
-11.95
-36.94%
CH:GALE
Galenica AG
85.75
15.29
21.70%

Bachem Holding AG Corporate Events

Bachem Mourns the Passing of Founder Peter Grogg
Jun 3, 2025

Bachem mourns the loss of its founder, Dr. h.c. Peter Grogg, who passed away at 83. Grogg, who founded the company in 1971, was instrumental in transforming Bachem into a world leader in peptide synthesis, leaving a significant mark on the firm and Swiss economic history. His leadership spanned over three decades, during which he served as CEO and later as chairman of the board. The announcement highlights the deep impact Grogg had on Bachem’s operations and its standing in the industry.

The most recent analyst rating on (CH:BANB) stock is a Buy with a CHF100.00 price target. To see the full list of analyst forecasts on Bachem Holding AG stock, see the CH:BANB Stock Forecast page.

Bachem’s AGM 2025 Approves Board Proposals and Dividend
Apr 30, 2025

Bachem Holding AG announced that its Annual General Meeting 2025 approved all proposals from the Board of Directors, including a dividend of CHF 0.85 per share, to be paid on May 7, 2025. The meeting also saw the re-election of the President and Board members, the election of Dr. Simone Wyss Fedele to the Board, and the approval of various financial and sustainability reports. Forvis Mazars SA was appointed as the auditor for 2025. This approval reflects strong shareholder support and positions Bachem for continued stability and growth in the pharmaceutical and biotech sectors.

Bachem Proposes New Board Member with Extensive Life Sciences Experience
Apr 3, 2025

Bachem Holding AG announced the proposal of Dr. Simone Wyss Fedele, CEO of Switzerland Global Enterprise, for election as a new member of its Board of Directors at the upcoming General Meeting in April 2025. Dr. Fedele brings extensive experience in the life sciences industry and international trade, having held leadership roles at Novartis and Takeda Pharmaceuticals. Her addition is expected to enhance Bachem’s strategic positioning and strengthen its board with her international expertise and connections.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.